116 related articles for article (PubMed ID: 12523492)
1. Effect of repeated treatment with mirtazapine on the central dopaminergic D2/D3 receptors.
Rogóz Z; Wróbel A; Dlaboga D; Dziedzicka-Wasylewska M
Pol J Pharmacol; 2002; 54(4):381-9. PubMed ID: 12523492
[TBL] [Abstract][Full Text] [Related]
2. Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors.
Rogoz Z; Wrobel A; Dlaboga D; Maj J; Dziedzicka-Wasylewska M
J Physiol Pharmacol; 2002 Mar; 53(1):105-16. PubMed ID: 11939713
[TBL] [Abstract][Full Text] [Related]
3. Effect of repeated treatment with reboxetine on the central alpha 1-adrenergic and dopaminergic receptors.
Rogóz Z; Margas W; Skuza G; Solich J; Kuśmider M; Dziedzicka-Wasylewska M
Pol J Pharmacol; 2002; 54(6):593-603. PubMed ID: 12866714
[TBL] [Abstract][Full Text] [Related]
4. Effect of combined treatment with imipramine and amantadine on the central dopamine D2 and D3 receptors in rats.
Rogóz Z; Dlaboga D; Dziedzicka-Wasylewska M
J Physiol Pharmacol; 2003 Jun; 54(2):257-70. PubMed ID: 12832726
[TBL] [Abstract][Full Text] [Related]
5. Effect of antidepressant drugs administered repeatedly on the dopamine D3 receptors in the rat brain.
Maj J; Dziedzicka-Wasylewska M; Rogoz R; Rogóz Z
Eur J Pharmacol; 1998 Jun; 351(1):31-7. PubMed ID: 9698202
[TBL] [Abstract][Full Text] [Related]
6. Effect of repeated treatment with tianeptine and fluoxetine on central dopamine D(2) /D(3) receptors.
Dziedzicka-Wasylewska M; Rogoz Z; Skuza G; Dlaboga D; Maj J
Behav Pharmacol; 2002 Mar; 13(2):127-38. PubMed ID: 11981225
[TBL] [Abstract][Full Text] [Related]
7. Effect of repeated treatment with milnacipran on the central dopaminergic system.
Rogóz Z; Margas W; Dlaboga D; Góralska M; Dziedzicka-Wasylewska M; Maj J
Pol J Pharmacol; 2000; 52(2):83-92. PubMed ID: 10949109
[TBL] [Abstract][Full Text] [Related]
8. [3H]quinpirole binding to putative D2 and D3 dopamine receptors in rat brain and pituitary gland: a quantitative autoradiographic study.
Levant B; Grigoriadis DE; DeSouza EB
J Pharmacol Exp Ther; 1993 Feb; 264(2):991-1001. PubMed ID: 8437136
[TBL] [Abstract][Full Text] [Related]
9. Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats.
Le Foll B; Diaz J; Sokoloff P
Synapse; 2003 Mar; 47(3):176-83. PubMed ID: 12494400
[TBL] [Abstract][Full Text] [Related]
10. Repeated imipramine treatment enhances the 7-OH-DPAT-induced hyperactivity in rats: the role of dopamine D2 and D3 receptors.
Rogóz Z; Skuza G
Pol J Pharmacol; 2001; 53(6):571-6. PubMed ID: 11985330
[TBL] [Abstract][Full Text] [Related]
11. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
Brocco M; Dekeyne A; Papp M; Millan MJ
Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388
[TBL] [Abstract][Full Text] [Related]
12. Effects of antidepressant drugs on the dopamine D2/D3 receptors in the rat brain differentiated by agonist and antagonist binding--an autoradiographic analysis.
Rogoz R; Dziedzicka-Wasylewska M
Naunyn Schmiedebergs Arch Pharmacol; 1999 Mar; 359(3):178-86. PubMed ID: 10208304
[TBL] [Abstract][Full Text] [Related]
13. The effect of repeated treatment with pramipexole on the central dopamine D3 system.
Maj J; Rogói Z; Margas W; Kata M; Dziedzicka-Wasylewska M
J Neural Transm (Vienna); 2000; 107(12):1369-79. PubMed ID: 11458990
[TBL] [Abstract][Full Text] [Related]
14. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
[TBL] [Abstract][Full Text] [Related]
15. Enhanced apomorphine sensitivity and increased binding of dopamine D2 receptors in nucleus accumbens in prepubertal rats after neonatal blockade of the dopamine D3 receptors by (+)-S14297.
Flores-Tochihuitl J; Vargas G; Morales-Medina JC; Rivera G; De La Cruz F; Zamudio S; Flores G
Synapse; 2008 Jan; 62(1):40-9. PubMed ID: 17957737
[TBL] [Abstract][Full Text] [Related]
16. Alterations in dopamine D3 receptors in the circling (ci3) rat mutant.
Schirmer M; Nobrega JN; Harrison SJ; Löscher W
Neuroscience; 2007 Feb; 144(4):1462-9. PubMed ID: 17187934
[TBL] [Abstract][Full Text] [Related]
17. Central effects of repeated treatment with CGP 37849, a competitive NMDA receptor antagonist with potential antidepressant activity.
Maj J; Klimek V; Gołembiowska K; Rogóz Z; Skuza G
Pol J Pharmacol; 1993; 45(5-6):455-66. PubMed ID: 7912134
[TBL] [Abstract][Full Text] [Related]
18. D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period.
Joyce JN
Synapse; 2001 May; 40(2):137-44. PubMed ID: 11252025
[TBL] [Abstract][Full Text] [Related]
19. Long-term exposure of rats to tramadol alters brain dopamine and alpha 1-adrenoceptor function that may be related to antidepressant potency.
Faron-Górecka A; Kuśmider M; Inan SY; Siwanowicz J; Piwowarczyk T; Dziedzicka-Wasylewska M
Eur J Pharmacol; 2004 Oct; 501(1-3):103-10. PubMed ID: 15464068
[TBL] [Abstract][Full Text] [Related]
20. Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.
Joyce JN; Der TC; Renish L; Osredkar T; Hagner D; Reploge M; Sakakibara S; Ueda S
Exp Neurol; 2004 May; 187(1):178-89. PubMed ID: 15081599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
